These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24138717)

  • 1. Approaching the increasing complexity of non-small cell lung cancer taxonomy.
    Maugeri-Sacca M; Bartucci M; Pagliuca A; Patrizii M; Signore M; De Maria R
    Curr Pharm Des; 2014; 20(24):3973-81. PubMed ID: 24138717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 16th World Conference on Lung Cancer.
    Landman A
    Lancet Oncol; 2015 Oct; 16(13):1290. PubMed ID: 26387750
    [No Abstract]   [Full Text] [Related]  

  • 3. Innovative Clinical Trials: The LUNG-MAP Study.
    Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
    Clin Pharmacol Ther; 2015 May; 97(5):488-91. PubMed ID: 25676724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?
    Galvani E; Toffalorio F; Peters GJ; De Pas T; Giovannetti E
    Curr Pharm Des; 2014; 20(24):3863-74. PubMed ID: 24138720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
    Wijesinghe P; Bollig-Fischer A
    Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Targeted therapies in non-small cell lung cancer in 2014].
    Leduc C; Besse B
    Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
    Cottini F; Lautenschlaeger T
    Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decade of advances in treatment for advanced non-small cell lung cancer.
    Gettinger S; Lynch T
    Clin Chest Med; 2011 Dec; 32(4):839-51. PubMed ID: 22054890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.
    Guernet A; Mungamuri SK; Cartier D; Sachidanandam R; Jayaprakash A; Adriouch S; Vezain M; Charbonnier F; Rohkin G; Coutant S; Yao S; Ainani H; Alexandre D; Tournier I; Boyer O; Aaronson SA; Anouar Y; Grumolato L
    Mol Cell; 2016 Aug; 63(3):526-38. PubMed ID: 27453044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.
    Bennouna J
    Future Oncol; 2017 Sep; 13(21):1829-1833. PubMed ID: 28657354
    [No Abstract]   [Full Text] [Related]  

  • 17. [Phenotypical plasticity and targeted therapies in non-small cell lung carcinomas].
    Da Silva J; Dalstein V; Polette M; Nawrocki-Raby B
    Rev Mal Respir; 2019 Apr; 36(4):438-441. PubMed ID: 31010761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
    Kuribayashi K; Funaguchi N; Nakano T
    J Cancer Res Ther; 2016; 12(2):528-34. PubMed ID: 27461605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How should "RET positive" NSCLC be treated?
    Smit EF
    Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.